China's rise as a health tech superpower is important

This summarizes an interview with Ruby Wang about China’s rapid ascent in health technology and biotech. China has layered digital care onto ubiquitous apps like WeChat and Alipay, normalizing telemedicine, AI doctor avatars, and app-based hospital booking to tackle urban-rural gaps and weak primary care. A deep talent pool, an efficient clinical testing system, large patient cohorts, lower running costs and state-directed incentives have accelerated drug development: China now runs more clinical trials than the U.S. and accounts for roughly half to 60% of global drug out-licensing, prompting major deals with Western firms such as Pfizer. Strengths concentrate in oncology, hardware, and scaling manufacturing; weaknesses include less maturity in advanced immunology areas and limited commercialisation expertise, which helps explain heavy out-licensing.

The global reaction mixes admiration with security-driven suspicion; U.S. measures like the Biosecure Act, COINS Act and BINSA are already constraining collaboration and investment. China’s Five-Year plans prioritize brain-computer interfaces and fast-tracked devices - Neuracle’s NEO invasive BCI received commercial approval in March 2026 - and Chinese firms export affordable ultrasound machines, surgical robots and wellness hardware that are highly relevant for developing countries. Cultural differences matter: Chinese health systems prioritize convenience and rapid deployment, whereas Western systems emphasize pre-emptive risk control. The result is a reshaping of where drugs and scalable health technologies originate and who gains access.